<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BMS-262084 is a 4-carboxy-2-azetidinone-containing irreversible inhibitor of FXIa, which is selective over other coagulation proteases </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the in vitro and in vivo properties of BMS-262084 in rabbits </plain></SENT>
<SENT sid="2" pm="."><plain>Studies were conducted in arteriovenous-shunt <z:mp ids='MP_0005048'>thrombosis</z:mp> (AVST), <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> (VT), electrolytic-mediated carotid <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> (ECAT) and cuticle <z:mp ids='MP_0001914'>bleeding</z:mp> time (BT) models </plain></SENT>
<SENT sid="3" pm="."><plain>BMS-262084 was infused IV from 1 h before <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> induction or cuticle transection to the end of the experiment </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro, BMS-262084 <z:hpo ids='HP_0003645'>prolonged activated partial thromboplastin time</z:hpo> (aPTT) with EC(2x) (concentration required to double aPTT) of 10.6 μM in rabbit plasma, and did not prolong prothrombin time (PT), thrombin time (TT) and HepTest </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, BMS-262084 produced dose-dependent antithrombotic effects in rabbits with antithrombotic ED(50) (dose that reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight or increased blood flow by 50% of the control) in AVST, VT and ECAT of 0.4, 0.7 and 1.5 mg/kg/h IV, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>BMS-262084 increased ex vivo aPTT dose-dependently without changes in PT and TT </plain></SENT>
<SENT sid="7" pm="."><plain>The antithrombotic effect of BMS-262084 was significantly correlated with its ex vivo aPTT, supporting the use of ex vivo aPTT as a pharmacodynamic biomarker </plain></SENT>
<SENT sid="8" pm="."><plain>BMS-262084 did not alter ex vivo rabbit platelet aggregation to <z:chebi fb="13" ids="16761">ADP</z:chebi> and collagen </plain></SENT>
<SENT sid="9" pm="."><plain>BT (fold-increase) determined at 3 and 10 mg/kg/h of BMS-262084 were 1.17 ± 0.04 and 1.52 ± 0.07*, respectively (*P &lt; 0.05 vs. control) </plain></SENT>
<SENT sid="10" pm="."><plain>This study demonstrated that BMS-262084 prevented experimental <z:mp ids='MP_0005048'>thrombosis</z:mp> at doses with low BT effects in rabbits, and suggests that a small molecule FXIa inhibitor may represent a promising antithrombotic therapy </plain></SENT>
</text></document>